Elabela/toddler: New peptide with a promising future in cancer diagnostic and therapy

Biochimica et biophysica acta. Molecular cell research, Aug 2021

Benjamin Liet, Nicolas Nys, Geraldine Siegfried

doi: 10.1016/j.bbamcr.2021.119065



Elabela/toddler is the second endogenous ligand recently identified after Apelin, that binds to the G protein-coupled receptor APJ. Elabela is a 54-amino acid peptide initially identified in fish and human genomes and classified as noncoding. This precursor can be cleaved to shorter sequences (32, 21, and 11 amino acids), which bind and activate APJ, and can be blocked by APJ antagonists. Contrary to Apelin and APJ, widely distributed in organs and tissues, Elabela expression is more restricted, and different studies have revealed the potential role of Elabela in cancers. This review summarizes the current studies focusing on the role of Elabela in different cancers.

Keywords: APJ; Cancer; ELABELA; Therapeutic targets.